% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Borchers:142297,
      author       = {S. Borchers and C. Maβlo and C. A. Müller and A. Tahedl
                      and J. Volkind and Y. Nowak$^*$ and V. Umansky$^*$ and J.
                      Esterlechner and M. H. Frank and C. Ganss and M. A. Kluth
                      and J. Utikal$^*$},
      title        = {{D}etection of {ABCB}5 tumour antigen-specific {CD}8+ {T}
                      cells in melanoma patients and implications for
                      immunotherapy.},
      journal      = {Clinical and experimental immunology},
      volume       = {191},
      number       = {1},
      issn         = {0009-9104},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell52004},
      reportid     = {DKFZ-2019-00080},
      pages        = {74 - 83},
      year         = {2018},
      abstract     = {ATP binding cassette subfamily B member 5 (ABCB5) has been
                      identified as a tumour-initiating cell marker and is
                      expressed in various malignancies, including melanoma.
                      Moreover, treatment with anti-ABCB5 monoclonal antibodies
                      has been shown to inhibit tumour growth in
                      xenotransplantation models. Therefore, ABCB5 represents a
                      potential target for cancer immunotherapy. However, cellular
                      immune responses against ABCB5 in humans have not been
                      described so far. Here, we investigated whether
                      ABCB5-reactive T cells are present in human melanoma
                      patients and tested the applicability of ABCB5-derived
                      peptides for experimental induction of human T cell
                      responses. Peripheral blood mononuclear cells (PBMNC)
                      isolated from blood samples of melanoma patients
                      (n = 40) were stimulated with ABCB5 peptides, followed
                      by intracellular cytokine staining (ICS) for interferon
                      (IFN)-γ and tumour necrosis factor (TNF)-α. To evaluate
                      immunogenicity of ABCB5 peptides in naive healthy donors,
                      CD8 T cells were co-cultured with ABCB5 antigen-loaded
                      autologous dendritic cells (DC). ABCB5 reactivity in
                      expanded T cells was assessed similarly by ICS.
                      ABCB5-reactive CD8+ T cells were detected ex vivo in 19 of
                      29 patients, melanoma antigen recognised by T cells
                      (MART-1)-reactive CD8+ T cells in six of 21 patients. In
                      this small, heterogeneous cohort, reactivity against ABCB5
                      was significantly higher than against MART-1. It occurred
                      significantly more often and independently of clinical
                      characteristics. Reactivity against ABCB5 could be induced
                      in 14 of 16 healthy donors in vitro by repeated stimulation
                      with peptide-loaded autologous DC. As ABCB5-reactive CD8 T
                      cells can be found in the peripheral blood of melanoma
                      patients and an ABCB5-specific response can be induced in
                      vitro in naive donors, ABCB5 could be a new target for
                      immunotherapies in melanoma.},
      keywords     = {ABCB5 protein, human (NLM Chemicals) / ATP Binding Cassette
                      Transporter, Subfamily B, Member 1 (NLM Chemicals) /
                      Antigens, Neoplasm (NLM Chemicals) / Cytokines (NLM
                      Chemicals) / Epitopes, T-Lymphocyte (NLM Chemicals) /
                      Peptides (NLM Chemicals)},
      cin          = {G300},
      ddc          = {570},
      cid          = {I:(DE-He78)G300-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28940439},
      pmc          = {pmc:PMC5721238},
      doi          = {10.1111/cei.13053},
      url          = {https://inrepo02.dkfz.de/record/142297},
}